메뉴 건너뛰기




Volumn 23, Issue 24, 2013, Pages 6620-6624

Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)

Author keywords

Hypocretin; Insomnia; Orexin receptor antagonists; Rat sleep EEG; Selective orexin 2 receptor antagonists

Indexed keywords

2,5 DIARYLNICOTINAMIDE DERIVATIVE; ALMOREXANT; FILOREXANT; HYPNOTIC SEDATIVE AGENT; JNJ 10397049; NICOTINAMIDE DERIVATIVE; OREXIN; OREXIN 2 RECEPTOR; OREXIN 2 RECEPTOR ANTAGONIST; SB 649868; SUVOREXANT; UNCLASSIFIED DRUG;

EID: 84888874211     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.10.045     Document Type: Article
Times cited : (21)

References (32)
  • 6
    • 84888867024 scopus 로고    scopus 로고
    • Actelion presentations, World Sleep Congress, Cairns, Australia, September 3-6, 2007. Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1)
    • Actelion presentations, World Sleep Congress, Cairns, Australia, September 3-6, 2007. Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1); http://www.clinicaltrials.gov/ct2/show/NCT00608985?term= almorexant+phase+III&rank=1.
  • 8
    • 84888869144 scopus 로고    scopus 로고
    • Merck & Co., Inc. presentation San Francisco, CA, United States, March 21-25, 2010. Discovery of MK-4305: A novel orexin receptor antagonist for the treatment of insomnia
    • Merck & Co., Inc. presentation, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010. Discovery of MK-4305: A novel orexin receptor antagonist for the treatment of insomnia.
    • 239th ACS National Meeting
  • 10
    • 84888863134 scopus 로고    scopus 로고
    • GSK presentations Seattle Washington, June 6-11
    • GSK presentations, APSS SLEEP Conference, Seattle Washington, June 6-11, 2009.
    • (2009) APSS SLEEP Conference


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.